Jason Katz, MD
Advanced Heart Failure and Transplant Cardiology · Chapel Hill, NCNPI 1417081654
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,200 of the $43,847 with a category attached, or 87.1%. 13 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 53.9% of the total. Reporting peaked in 2024 at $25,731 and has fallen 63.2% since, to $9,476 in 2025.
Across 78 payments — averaging $562.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$24K
- Abiomed$18K
- Abbott$2K
- Cvrx, Inc.$239
- Getinge USA Sales, LLC$226
- Teleflex LLC$132
- plus $352 from 7 others
Across 14 payments — averaging $4144.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$58K
What the payments were for
- Consulting fees$1,3003%
- Speaking & faculty fees$38,20087%
- Travel & lodging$8442%
- Food & beverage$3,4438%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $23,648 |
| Abiomed | 24 | $17,579 |
| Abbott | 24 | $1,671 |
| Cvrx, Inc. | 2 | $239 |
| Getinge USA Sales, LLC | 4 | $226 |
| Teleflex LLC | 1 | $132 |
| AstraZeneca | 1 | $121 |
| Angiodynamics, Inc. | 2 | $58 |
| Chiesi USA, Inc. | 1 | $54 |
| La Jolla Pharmaceutical Company | 1 | $49 |
| One Lambda, Inc. | 1 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$23,614
- Impella$15,349
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$506
- Barostim Neo System$215
- HeartMate 3 Left Ventricular Dev$150
- CARDIOMEMS$147
- Arrow$132
- CardioMEMS HF System$118
- CARDIOHELP$112
How this compares
$43,847 in reported general payments places this provider in the 65th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
See all advanced heart failure and transplant cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 20 | $15,280 |
| EntrestoSacubitril/Valsartan | 11 | $13,459 |
| Metoprolol Succinate | 13 | $124 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Chapel Hill
- Elizabeth VolzChapel Hill$18K
- William MostertzChapel Hill$3K
- Patricia ChangChapel Hill$697
- Brian JensenChapel Hill$55
- Daniel BensimhonGreensboro$2.1M
- Stephen GreeneDurham$582K
- John RommelWilmington$263K
- Stephen ZouzoulasConcord$244K
- Hassan AlhosainiWinston Salem$195K
- Vinay ThohanAsheville$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.